RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy GenglycosZacks Investment Research • 08/20/26
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a TranscriptSeeking Alpha • 08/20/26
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)GlobeNewsWire • 08/19/26
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/05/26
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate UpdateGlobeNewsWire • 08/04/26
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate UpdateGlobeNewsWire • 07/28/26
Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to DeclineZacks Investment Research • 07/28/26
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE)GlobeNewsWire • 07/15/26
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global ImpactGlobeNewsWire • 07/08/26
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/29/26
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law FirmPRNewsWire • 06/04/26
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/04/26
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewsWire • 06/03/26